Damora Therapeutics, Inc. (DMRA)

Market Cap	1.08B +6,293.6%
Revenue (ttm)	n/a
Net Income	-241.25M
EPS	-9.88
Shares Out	61.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,797
Open	18.69
Previous Close	18.74
Day's Range	17.50 - 18.69
52-Week Range	4.95 - 38.33
Beta	1.44
Analysts	Strong Buy
Price Target	46.89 (+168.1%)
Est. Earnings	Nov 5, 2026

About DMRA

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 7
• Stock Exchange: Nasdaq
• Ticker Symbol: DMRA
• Website: https://www.damoratx.com

Analyst Summary

According to 10 analysts, the average rating for DMRA stock is "Strong Buy." The 12-month stock price target is $46.89, which is an increase of 168.10% from the latest price.

Price Target

$46.89

(168.10% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error